Ignite Creation Date:
2025-12-24 @ 5:14 PM
Ignite Modification Date:
2026-01-05 @ 11:34 PM
Study NCT ID:
NCT05918250
Status:
WITHDRAWN
Last Update Posted:
2023-08-18
First Post:
2023-06-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Sponsor:
ModernaTX, Inc.
Organization:
Study Overview
Official Title:
A Phase 1, Open-Label, Multicenter, Study of mRNA-2736 in Patients With Relapsed or Refractory Multiple Myeloma
Status:
WITHDRAWN
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The Sponsor decided to discontinue development of mRNA-2736 for strategic business reasons.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to evaluate the safety and tolerability of mRNA-2736 in participants with RRMM.
Detailed Description:
This open-label, Phase 1, dose-escalation, first-in-human (FIH) clinical study of mRNA-2736 in participants with RRMM is designed to evaluate the safety and tolerability of escalating doses of mRNA-2736, administered intravenously (IV), to determine maximum tolerated dose and/or recommended Phase 2 dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of mRNA-2736.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2023-503286-38-00 | REGISTRY | CTIS (EU) | View |